为您找到相关结果约500个

你是不是要搜索 期刊Axicabtagene Cilouleucel 点击跳转

Axicabtagene effective in indolent NHL

Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Axicabtagene ciloleucel for CD19+plasmablastic lymphoma

Assessing readmission after axicabtagene ciloleucel immunotherapy.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel

Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel

Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas

Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

Axicabtagene Ciloleucel Demonstrates Improved ORR in Indolent Non-Hodgkin Lymphoma

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

为您找到相关结果约500个

共500条页码: 1/34页15条/页